Capital World Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital World Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3B	Sell	25,368,124 -142,058	-0.6%	-$66.2M	1.55%	11
2025 Q4	$11.6B	Sell	25,510,182 -400,405	-2%	-$173M	1.57%	10
2025 Q3	$10.1B	Sell	25,910,587 -2,821,556	-10%	-$1.18B	1.39%	11
2025 Q2	$12.8B	Buy	28,732,143 +198,835	+0.7%	+$91.6M	1.86%	9
2025 Q1	$13.8B	Buy	28,533,308 +207,613	+0.7%	+$96.7M	2.24%	7
2024 Q4	$11.4B	Buy	28,325,695 +1,514,993	+6%	+$702M	1.73%	9
2024 Q3	$12.5B	Buy	26,810,702 +102,736	+0.4%	+$49.4M	1.93%	8
2024 Q2	$12.5B	Buy	26,707,966 +1,140,782	+4%	+$495M	2.04%	7
2024 Q1	$10.7B	Buy	25,567,184 +3,761,414	+17%	+$1.59B	1.77%	8
2023 Q4	$8.87B	Buy	21,805,770 +3,824,103	+21%	+$1.41B	1.58%	10
2023 Q3	$6.25B	Buy	17,981,667 +641,033	+4%	+$224M	1.24%	13
2023 Q2	$6.1B	Buy	17,340,634 +1,196,211	+7%	+$403M	1.17%	15
2023 Q1	$5.09B	Buy	16,144,423 +3,375,417	+26%	+$1.01B	1.05%	18
2022 Q4	$3.69B	Buy	12,769,006 +244,327	+2%	+$74.5M	0.79%	27
2022 Q3	$3.63B	Sell	12,524,679 -45,253	-0.4%	-$13M	0.81%	23
2022 Q2	$3.54B	Sell	12,569,932 -96,198	-0.8%	-$25.7M	0.75%	25
2022 Q1	$3.31B	Buy	12,666,130 +1,145,275	+10%	+$272M	0.57%	38
2021 Q4	$2.53B	Buy	11,520,855 +478,553	+4%	+$93.1M	0.4%	59
2021 Q3	$2B	Buy	11,042,302 +26,924	+0.2%	+$5.26M	0.34%	75
2021 Q2	$2.22B	Buy	11,015,378 +1,357,903	+14%	+$284M	0.38%	70
2021 Q1	$2.08B	Buy	9,657,475 +3,320	+0%	+$729K	0.38%	66
2020 Q4	$2.28B	Sell	9,654,155 -1,706,360	-15%	-$392M	0.44%	54
2020 Q3	$3.09B	Sell	11,360,515 -1,127,728	-9%	-$311M	0.68%	33
2020 Q2	$3.63B	Sell	12,488,243 -91,475	-0.7%	-$24.8M	0.88%	23
2020 Q1	$2.99B	Buy	12,579,718 +1,981,607	+19%	+$455M	0.87%	28
2019 Q4	$2.32B	Buy	10,598,111 +11,278	+0.1%	+$2.28M	0.52%	49
2019 Q3	$1.79B	Sell	10,586,833 -862,721	-8%	-$153M	0.43%	68
2019 Q2	$2.1B	Buy	11,449,554 +535,827	+5%	+$93.7M	0.49%	54
2019 Q1	$2.01B	Buy	10,913,727 +1,033,361	+10%	+$191M	0.49%	56
2018 Q4	$1.64B	Buy	9,880,366 +2,181,475	+28%	+$378M	0.44%	60
2018 Q3	$1.48B	Sell	7,698,891 -3,293,143	-30%	-$586M	0.36%	74
2018 Q2	$1.87B	Buy	10,992,034 +1,993,107	+22%	+$309M	0.4%	65
2018 Q1	$1.47B	Buy	8,998,927 +3,109,444	+53%	+$508M	0.33%	84
2017 Q4	$883M	Sell	5,889,483 -5,672,358	-49%	-$840M	0.19%	123
2017 Q3	$1.76B	Sell	11,561,841 -3,854,581	-25%	-$580M	0.4%	67
2017 Q2	$1.99B	Sell	15,416,422 -2,484,511	-14%	-$299M	0.47%	59
2017 Q1	$1.96B	Sell	17,900,933 -2,857,200	-14%	-$252M	0.47%	60
2016 Q4	$1.53B	Sell	20,758,133 -1,534,250	-7%	-$125M	0.38%	69
2016 Q3	$1.94B	Buy	22,292,383 +599,586	+3%	+$56.7M	0.51%	51
2016 Q2	$1.87B	Buy	21,692,797 +94,635	+0.4%	+$8.18M	0.5%	51
2016 Q1	$1.72B	Buy	21,598,162 +860,251	+4%	+$77.8M	0.47%	52
2015 Q4	$2.61B	Sell	20,737,911 -174,194	-0.8%	-$21M	0.73%	31
2015 Q3	$2.18B	Sell	20,912,105 -1,109,315	-5%	-$143M	0.64%	39
2015 Q2	$2.72B	Sell	22,021,420 -1,427,057	-6%	-$180M	0.74%	38
2015 Q1	$2.77B	Sell	23,448,477 -1,160,000	-5%	-$139M	0.75%	36
2014 Q4	$2.92B	Sell	24,608,477 -1,048,700	-4%	-$118M	0.79%	35
2014 Q3	$2.88B	Sell	25,657,177 -725,000	-3%	-$69M	0.81%	31
2014 Q2	$2.5B	Sell	26,382,177 -357,500	-1%	-$25.1M	0.69%	39
2014 Q1	$1.89B	Buy	26,739,677 +1,222,800	+5%	+$96.8M	0.54%	52
2013 Q4	$1.9B	Buy	25,516,877 +497,000	+2%	+$34.6M	0.53%	47
2013 Q3	$1.9B	Buy	25,019,877 +1,068,200	+4%	+$85M	0.58%	46
2013 Q2	$1.91B	Buy	+23,951,677	New	+$1.76B	0.62%	42

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital World Investors's VRTX Position: Q1 2026 in Review

Capital World Investors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.56% in Q1 2026, selling an estimated $66.2M and leaving 25,368,124 shares worth $11.3B. The position accounts for 1.55% of the portfolio, ranked #11.

Capital World Investors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.8B in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Capital World Investors held 25,368,124 shares of Vertex Pharmaceuticals worth $11.3B as of Q1 2026.
Capital World Investors sold 142,058 Vertex Pharmaceuticals shares in Q1 2026, an estimated $66.2M.
Vertex Pharmaceuticals made up 1.55% of Capital World Investors's portfolio in Q1 2026, its #11 holding.
Capital World Investors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Capital World Investors's Vertex Pharmaceuticals position peaked at $13.8B in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capital World Investors's 13F filing for Q1 2026, filed 13 May 2026.